184 related articles for article (PubMed ID: 33628041)
1. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
Wu L; Li B
Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
[TBL] [Abstract][Full Text] [Related]
2. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
3. New-onset insulin-dependent diabetes due to nivolumab.
Zaied AA; Akturk HK; Joseph RW; Lee AS
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29623210
[TBL] [Abstract][Full Text] [Related]
4. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
5. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.
Hernandez A; Zeidan B; Desai P; Frunzi J
Cureus; 2021 Feb; 13(2):e13302. PubMed ID: 33738153
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
Kichloo A; Albosta MS; McMahon S; Movsesian K; Wani F; Jamal SM; Aljadah M; Singh J
J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561
[TBL] [Abstract][Full Text] [Related]
12. DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.
Farah SJ; Masri N; Ghanem H; Azar M
AACE Clin Case Rep; 2020; 6(6):e349-e351. PubMed ID: 33244501
[TBL] [Abstract][Full Text] [Related]
13. A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma.
Salangsang J; Sapkota S; Kharel S; Gupta P; Kalla A
Cureus; 2023 Feb; 15(2):e35276. PubMed ID: 36825072
[TBL] [Abstract][Full Text] [Related]
14. Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab.
Cuenca JA; Laserna A; Reyes MP; Nates JL; Botz GH
Case Rep Crit Care; 2020; 2020():8671530. PubMed ID: 32274219
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune diabetes from pembrolizumab: A case report and review of literature.
Bhanderi H; Khalid F; Bodla ZH; Muhammad T; Du D; Meghal T
World J Clin Oncol; 2023 Nov; 14(11):535-543. PubMed ID: 38059185
[TBL] [Abstract][Full Text] [Related]
16. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
17. New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report.
Pachpande V; Mullangi S; Lekkala MR; Patel A
Cureus; 2022 Apr; 14(4):e24479. PubMed ID: 35651416
[TBL] [Abstract][Full Text] [Related]
18. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Kusuki K; Suzuki S; Mizuno Y
Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.
Alrifai T; Ali FS; Saleem S; Ruiz DCM; Rifai D; Younas S; Qureshi F
Case Rep Oncol Med; 2019; 2019():8781347. PubMed ID: 31781446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
